[Use of licopid and viferon in the course of radiotherapy for endometrial carcinoma].
Zinchenko
M V
MV
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000627:therapeutic use*; D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D019610:Cytoprotection / Q000187:drug effects; D016889:Endometrial Neoplasms / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000528:radiation effects; D008875:Middle Aged; D009367:Neoplasm Staging; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D007370:Interferon Type I; D011994:Recombinant Proteins; D000119:Acetylmuramyl-Alanyl-Isoglutamine